Literature DB >> 2355230

Competitive inhibition of N-acetylated-alpha-linked acidic dipeptidase activity by N-acetyl-L-aspartyl-beta-linked L-glutamate.

V Serval1, L Barbeito, A Pittaluga, A Cheramy, S Lavielle, J Glowinski.   

Abstract

The endogenous neuropeptide N-acetyl-L-aspartyl-L-glutamate (NAAG) fulfills several criteria required to be accepted as a neurotransmitter. NAAG inactivation may proceed through enzymatic hydrolysis into N-acetyl-L-aspartate and glutamate by an N-acetylated-alpha-linked acidic dipeptidase (NAALADase). Therefore, some properties of NAALADase activity were investigated using crude membranes from the rat forebrain. Kinetic parameters of the hydrolysis of [Glu-3H]NAAG were determined first (Km = 0.40 +/- 0.05 microM; Vmax = 155 +/- 20 pmol/min/mg of protein). The enzymatic activity, i.e., NAALADase, was inhibited noncompetitively by the glutamatergic agonist quisqualate (Ki = 1.9 +/- 0.3 microM), and competitively by N-acetyl-L-aspartyl-beta-linked L-glutamate (beta-NAAG; Ki = 0.70 +/- 0.05 microM). To determine whether glutamate-containing dipeptides, such as NAAG, beta-NAAG, N-acetyl-L-aspartyl-D-glutamate, L-aspartyl-L-glutamate, L-alanyl-L-glutamate, L-glutamyl-L-glutamate, and L-glutamyl-gamma-linked L-glutamate, were substrates of NAALADase, rat brain membranes were immobilized on a C-8 column. Thus, endogenous trapped glutamate was washed away and formation of unlabelled glutamate could be estimated using an o-phthaldialdehyde/reverse-phase HPLC detection procedure. beta-NAAG was shown to be a nonhydrolyzable competitive inhibitor of NAALADase. L-Aspartyl-L-glutamate was hydrolyzed faster than NAAG, suggesting that the acetylated moiety is not essential for NAALADase specificity. Rat brain membranes also contained nonspecific peptidase activities (insensitive to both quisqualate and beta-NAAG), which, in the case of L-alanyl-L-glutamate, for instance, accounted for all observed hydrolysis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2355230     DOI: 10.1111/j.1471-4159.1990.tb08818.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  N-Acetyl-aspartylglutamate (NAAG) in human cerebrospinal fluid: Determination by high performance liquid chromatography, and influence of biological variables.

Authors:  V Brovia; A Ricciardi; L Barbeito
Journal:  Amino Acids       Date:  1995-06       Impact factor: 3.520

2.  Maternal inflammation leads to impaired glutamate homeostasis and up-regulation of glutamate carboxypeptidase II in activated microglia in the fetal/newborn rabbit brain.

Authors:  Zhi Zhang; Bassam Bassam; Ajit G Thomas; Monica Williams; Jinhuan Liu; Elizabeth Nance; Camilo Rojas; Barbara S Slusher; Sujatha Kannan
Journal:  Neurobiol Dis       Date:  2016-06-17       Impact factor: 5.996

3.  Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II.

Authors:  R Luthi-Carter; U V Berger; A K Barczak; M Enna; J T Coyle
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

4.  Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.

Authors:  Jesse Alt; Marigo Stathis; Camilo Rojas; Barbara Slusher
Journal:  FASEB J       Date:  2013-03-23       Impact factor: 5.191

5.  Amino acids and N-acetyl-aspartyl-glutamate as neurotransmitter candidates in the monkey retinogeniculate pathways.

Authors:  R Molinar-Rode; P Pasik
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

6.  Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase.

Authors:  R E Carter; A R Feldman; J T Coyle
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

7.  N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats.

Authors:  Zheng-Xiong Xi; Michael Kiyatkin; Xia Li; Xiao-Qing Peng; Armina Wiggins; Krista Spiller; Jie Li; Eliot L Gardner
Journal:  Neuropharmacology       Date:  2009-06-24       Impact factor: 5.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.